Precursor B-cell acute lymphoblastic leukemia (B-ALL) is associated with recurrent mutations that occur 21 in cancer-initiating cells. There is a need to understand how spontaneous driver mutations influence clonal 22 evolution in leukemia. The ETS-transcription factors PU.1 and Spi-B (encoded by Spi1 and Spib) execute 23 a critical role in B cell development and serve as complementary tumour suppressors by opposing the 24 proliferative events mediated by IL-7R signaling. Here, we used a mouse model to conditionally delete 25 Spi1 and Spib genes in developing B cells. These mice developed B-ALL with a median time to euthanasia 26 of 18 weeks. We performed RNA and whole-exome sequencing (WES) on leukemias isolated from Mb1-27
Introduction 35
Acute lymphoblastic leukemia is the most common type of childhood cancer, with approximately 36 6000 new cases diagnosed in the United States each year 1 . Most leukemias originate within the B cell 37 rather than the T cell lineage 2, 3 . Precursor B cell acute lymphoblastic leukemia (pre-B-ALL) is a disease 38 that is revealed by the presence of transformed precursor B cells in the blood, bone marrow, and tissues; 39
and is most common in 1-5 year old patients and have high levels of Janus Kinase (JAK)-STAT signaling to sustain survival and proliferation [5] [6] [7] .
44
Activating mutations of the IL7R gene have been described in human pre-B-ALL 8 . JAK and IL7R 45 mutations are frequent in several subtypes of pre-B-ALL including the recently described disease Ph-like 46 leukemia 9,10 . In summary, mutations that activate cytokine signaling, and impair differentiation, function 47 as driver mutations in pre-B-ALL. 48 PU.1 (encoded by SPI1) and Spi-B (encoded SPIB in mice) are transcription factors of the E26-49 transformation-specific (ETS) family 11 . These two proteins share a conserved DNA binding domain and 50 interact with an overlapping set of DNA binding sites within the genome 12 . PU.1 and Spi-B complement 51 one anothers function, and activate multiple genes involved in B cell receptor signaling [12] [13] [14] [15] . Lack of these 52 factors in developing B cells results in a block to B development at the small pre-B cell stage associated 53 with impaired Ig light chain rearrangement 15, 16 . Importantly, conditional deletion of Spi-B and PU.1 in 54 developing B-cells leads to high incidence of B-ALL in mice, but the mechanisms of leukemogenesis in 55 the absence of these transcription factors are still undetermined 17 . In conclusion, PU.1 and Spi-B are 56 required for B-cell development, and function as complementary tumour suppressors in the B cell lineage. 57 B cell neoplasms, like all cancers, are thought to be diseases in which there is clonal evolution 58 from a common precursor, in which acquired gene mutations drive an evolutionary natural selection 59 process 18, 19 . The mechanisms by which cancer-initiating cells respond to selection pressures during clonal 60 evolution have been classified into a number of common hallmarks 20 . In response to selection pressure, 61 the genetic makeup of cancer-initiating cells changes during the course of disease due to acquired 62 mutation. Mutations can be broadly classified as drivers or passengers 18, 21 . Driver mutations are those that 63 provide a growth advantage to a cancer clone, whereas passenger mutations do not provide a growth 64
advantage. Pediatric B-ALL is less curable upon relapse due to clonal evolution of the leukemia, resulting 65 in driver mutations inducing a more aggressive disease 22 . High levels of intratumoral heterogeneity of 66 mutations is a poor prognostic marker for leukemia 23 . Whole-exome or whole-genome sequencing of pre-67 B-ALL cases is expected to lead to a deeper understanding of the genetic causes of this disease, ultimately 68 permitting molecular targeted therapy for individual patients 2 . 69
In this study, we investigated the molecular features of leukemogenesis in a spontaneous model of 70 B-ALL induced by deletion of genes encoding PU.1 and Spi-B. We generated Mb1 +/Cre Spi1 lox/lox Spib -/-71 mice, called here Mb1-CreDPB mice 16 . We found that Mb1-CreDPB mice developed pre-B-ALL 72 characterized by the high expression of IL-7R, with a median time to euthanasia of 18 weeks. Using 73 whole-exome sequencing (WES) and RNA-seq, we identified single-nucleotide variants (SNVs), most of 74 which were predicted to have a role in the control of cell proliferation, communication and metabolism. 75 Strikingly, we identified recurrent SNVs in genes encoding Aiolos, Jak1, and Jak3 in mouse leukemias. 76
Further analysis revealed that SNVs located in Jak3 resulted in three different types of amino acid 77 substitutions within the pseudo-kinase domain (R653H, V670A) and kinase domain (T844M). We 78 confirmed the ability of these mutations to provide survival and proliferation advantages to normal pro-B 79 cells. In summary, this study shows that Jak3 mutations are secondary drivers of leukemogenesis in the 80 absence of Spi-B and PU.1. This mouse model may be useful to determine the effects of molecular targeted 81 therapies on intratumoral heterogeneity and clonal evolution in B-ALL. 82
Materials and Methods 83

Mice and breeding 84
Mb1-Cre mice have been described previously 24 
88
(referred to as Mb1-CreDB) mice were used as experimental controls. Mice were fed with regular chow 89 and tap water ad libitum and housed with a 12-h light-dark cycle. Mice showing signs of illness were 90 euthanized and examined for spleen, thymus and lymph node enlargement and analyzed as described 91 below. All experiments were performed in compliance with the Western University Council on Animal 92
Care. 93 94
Histology and microscopic analysis 95
Mb1-CreDPB mice showing signs of disease were euthanized by CO2 and spleen and thymus were 96 removed for histological analysis. Spleen and thymus removed from Mb1-CreDB mice were used as 97 control. Organs were fixed in 10% buffered formalin. Tissues were paraffin embedded, sectioned, and 98 stained with hematoxylin and eosin. High-resolution micrographs were captured using a Q-Color3 digital 99 camera (Olympus, Markham, ON, Canada). to perform exome target capture. Paired-end DNA library preparation was performed using SureSelectXT 116 Target Enrichment System. An Illumina HiSeq4000 instrument was used to perform the whole-exome 117 sequencing. BAM files were converted to Fastaq format on Galaxy suite 25 using "SAMtoFastaq" tool. 118
Fastaq reads had Illumina Adaptors were removed using TrimGalore!. Trimmed reads were aligned to the 119 mouse reference genome (mm10) using Bowtie. BAM aligned files were used as input for single somatic 120 variant callers. Somatic variants of three matched-tumour mouse samples were called by using two 121 independent methods, Strelka and Mutect 26,27 . For both methods, variants were called using the standard 122 settings recommend by the package documentation. VCF files containing the somatic nucleotide variants 123 (SNVs) and small insertions and deletions (INDELs) generated by Strelka and Mutect were further filtered 124 following the criteria 'passed' or 'keep' for the Strelka and Mutect outputs, respectively. Filtered VCF 125 files outputted by Strelka and Mutect were intersected using VCFtools and annotated using the SnpEff 28 126 package using the mouse genomic annotation (mm10). Annotated variants were classified according the 127 variant impact in HIGH, MODERATE, MODIFIER and LOW, and overlapping variants among the three 128 8 samples were determined. Independently, outputs generated by Strelka and Mutect were also annotated 129 using the SnpEff tool for further analysis. 130
131
RNA Sequencing 132
RNA was extracted from thymic tumours 853, 854 and 857 using RNeasy Kit (QIAGEN, ON,  133 Canada). RNA-sequencing was performed by McGill University and Génome Québec Innovation Centre 134 (Montreal, Canada). Paired-end (mRNA-sequencing stranded) libraries were prepared using Truseq 135 stranded total RNA library prep kit. Libraries were sequenced using an Illumina HiSeq4000 PE100 136 instrument. Data analysis was performed as described previously 16 . In summary, Standard Illumina 137 sequencing adaptors were removed using Trim Galore!. Trimmed Fastaq reads were aligned to the mouse 138 reference genome version mm10 using TopHat2 29 in mate-paired mode using Galaxy suite. Assembled 139 transcript abundance was determined as previously using Cufflinks
29
. 140
141
Sanger Sequencing 142
RNA extracted from 20 thymic leukemias was reversed transcribed to complementary DNA using 143 iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Primers flanking the Ikzf3, Jak3 and Jak1 mutations 144 identified by WES were designed using Primer-BLAST. cDNA was used as a template for PCR reactions 145 using specific primers (Sequences described in Supplementary Information). PCR reactions were run 146 in a 1.5% agarose gel and the PCR products were excised and purified from the gel using QIAquick Gel 147 Extraction Kit (QIAGEN, ON, Canada). Purified DNA was submitted for Sanger sequencing at London 148
Regional Genomics Centre, Western University (London, ON, Canada). Sequencing chromatograms and 149 DNA sequences were analyzed in the software 4Peaks (Mekentosj, Amsterdam). 150 9
DNA Constructs and Site-Directed Mutagenesis 152
The mouse MSCV-IRES-GFP-JAK3 plasmid was kindly provided by Dr. Kevin D. Bunting. 153 T844M, R653H, and V670A mutations were generated by site-directed mutagenesis using Q5® Site-154 Directed Mutagenesis Kit (New England BioLabs, Ipswich, MA). Site-directed mutagenesis primers for 155 each one of the specific mutations were designed using NEBaseChanger tool. Mutations were confirmed 156 by Sanger Sequencing before retroviral production and spinoculation. 157
158
Retroviral production and infection 159
Retroviral supernatants for wild-type Jak3, and T844M, R653H, V670A mutants were generated 160
Platinum-E retroviral packaging cells 30 using PEIPro transfection reagent (PolyPlus, New York, NY). 10 161 µg of MSCV plasmid were cotransfected with 4 µg pECO plasmid (Clontech, Mountain View, CA). 162
Plasmid DNA was mixed with polyethyleneimine (PEI) at a 2:1 PEI/DNA ratio and applied to 3 × 10 6 163 cells in a 10-cm plate. The medium was changed after overnight incubation, and virus-containing 164 supernatant was collected 48 hours after medium change. Wild-type pro-B cells were infected by 165 spinoculation with 1 mL of viral supernatant containing 10ul of polybrene at the concentration of 166 10mg/ml. Cells were centrifuged at 3000 × g for 2 hours at 30°C and allowed to recover for 24 hours 167 before medium change and infection was confirmed by flow cytometric analysis for GFP. 168
169
Cell Culture 170
Wild-type and Jak3 mutant-infected pro-B cell lines used in this study were cultured in IMDM 171 severe impairment to B cell development at the large pre-B to small pre-B cell transition in the bone marrow 190 of 6-10 week-old mice 16 . Mb1-CreDPB mice that express Cre recombinase and are deleted for Spi-B but are 191 homozygous for the wild type Spi1 allele were fertile and healthy. In contrast, Mb1-CreDPB mice had a 192 median survival of 18 weeks, at which point they required euthanasia due to signs of illness, including 193 lethargy and laboured breathing (Fig. 1A, 1B) . Dissection of euthanized mice revealed enlargement of the 194 spleen and thymus (Fig. 1A, 1C, 1D ). Histological analysis revealed that normal spleen and thymus 195 organization was completely effaced in moribund Mb1-CreDPB mice compared to the controls (Fig. 1E) . 196 CreDPB mice showed that 78% of leukemias had IgM and Igk on the cell surface (Fig. 2F, right panel) . 211
Most leukemias isolated from Mb1-CreDPB mice had IgH rearrangements, although fewer leukemias 212 expressed IgM at the cell surface (Fig. 2C) . In summary, these results show that leukemia cells begin to 213 appear in thymus and spleen of Mb1-CreDPB mice after 11 weeks of age. All leukemias in Mb1-CreDPB 214 mice at 11-26 weeks of age expressed IL-7R, but most did not express Ig on their cell surface, suggesting 215 that these cells resembled pro-B or large pre-B cells. 216 217
Whole-exome sequencing (WES) identifies somatic nucleotide variants in leukemias generated in the 218
lack of Spi-B and PU.1 219
As described above, Mb1-CreDPB mice had a variable time to requirement of euthanasia as well 220 as heterogeneity in Ig expression status of leukemias ( Fig. 1 and 2 ). This variability suggested that 221 secondary driver mutations are required to induce leukemia in addition to the initiating lesion of Spi1/Spib 222 deletion. In order to discover potential driver mutations in Mb1-CreDPB mice leukemias, we performed 223 whole-exome sequencing (WES) analysis of three mouse tumours, 853, 854, and 857, as well as on 224 matched genomic tail DNA as a control ( Supplementary Fig. 1 , data available in Supplementary 225 Information). Single Nucleotide Variants (SNVs) for each one of the samples were identified by 226 comparing leukemia and control tail DNA exome sequences using the Strelka somatic variant caller 26 . 227
The number of SNVs identified by Strelka differed for each one of the tumours, where sample 854 showed 228 the highest number of SNVs (3,887) ( Fig. 3A-C) . Samples 853 and 857 presented a very similar number 229 of SNVs, totaling 2,558 and 2,465, respectively. Although the tumours had a variable number of SNVs, 230 the distribution of the SNVs by chromosome followed a similar pattern in which chromosome 2 showed 231 13 the highest frequency of SNVs, followed by chromosome 11, chromosome 1 and chromosome 7 232 Fig. 2A-C) . The majority of the nucleotide alterations in the three tumours analyzed 233 Fig. 2D ). In order to gain insight into the nature of the 234 mutational processes in Mb1-CreDPB mice, we determined the mutational signature of leukemias using 235 were consistently flanked at the 3' base by an adenine (A) nucleotide (Supplementary Fig. 3D) . 245
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In order to increase the confidence in the SNVs identified by Strelka and to reduce the number of 246
SNVs without a potential biological function, somatic variants were called with a second variant discovery 247 method, Mutect 27 . Mutect detected fewer SNVs than Strelka (Fig. 3A-C) . The overlap of SNVs identified 248 by both methods was used to determine high confidence SNVs. We found that by using this strategy the 249 number of SNVs was reduced, resulting in 183 SNVs for sample 853, 293 SNVs for sample 854, and 199 250
SNVs for sample 857. High confidence SNVs were annotated using the mouse genome (mm10) using the 251 SnpEff tool, which also enables the prediction of the biological effect of the variants 28 . We found that the 252 majority of the high confidence SNVs were classified by as having or a MODIFIER or MODERATE 253 deleterious impact while a few SNVs were classified as HIGH (Fig. 3D) . We next looked at the effect of 254 SNVs classified as MODERATE and HIGH, and found that most of the SNVs classified as MODERATE 255 resulted in missense variants; while the few SNVs predicted as having HIGH impact caused the gain or loss 256 of stop codons, or alterations in splice acceptor or donor sites, defined by the two bases before exon start or 257 ends, respectively (Fig. 3E) . We next investigated whether there were common SNVs among the three mouse 258 tumours sequenced. Samples 854 and 857 showed common SNVs in the genes Sntg1, Brd8, Lrp5 and 259 Slco1b2 (Fig. 3F) . Samples 853 and 854 showed common SNVs in the genes Ryr2 and Skint6. Finally, 260 samples 853 and 857 showed common SNVs in the genes Ikzf3 and Jak3 (Fig. 3F) . Interestingly, Ikzf3 and 261 Jak3 are well-characterized driver mutations in human pre-B cell acute lymphoblastic leukemia 35 . The 262 identification of common Ikzf3 and Jak3 SNVs suggests that this approach is effective at identifying potential 263 driver mutations. 264
265
Mutations in Janus Kinase 1 and 3 (Jak1/Jak3) and Aiolos (Ikzf3) genes are potential secondary drivers 266 of leukemogenesis in Mb1-CreDPB mice 267
As cancer driver genes would be expected to contain mutations and be expressed 21 , we also performed 268 RNA-sequencing analysis on leukemias 853, 854, and 857 in order to assess gene expression levels. To filter 269 data based on levels of gene expression, Fragments Per Kilobase of transcript per Million mapped reads 270 (FPKM) was determined from RNA-seq data using Cufflinks. FPKM was plotted against VAF determined 271 using Strelka 26 for three mouse leukemias 853, 854, and 857. In each of the three samples there were highly 272 expressed genes that also had high VAF (Fig. 4A-C) . Importantly, sample 853 had high FPKM and VAF for 273 variants in Jak3 and Ikzf3 (Fig 4A) . Sample 854 had high FPKM and VAF for a variant in Jak1 (Fig 4B) . 274
Finally, sample 857 had high FPKM and VAF for variants in Jak3 and Ikzf3 (Fig 4C) . The elevated 275 expression levels added to the high VAF of Jak1, Jak3 and Ikzf3 genes in Mb1-CreDPB mice leukemias 276 supports the hypothesis that these variants represent secondary driver mutations. 277
Next, we sought to define the biological processes in which mutated genes could be involved by 278 performing gene ontology analysis in genes with VAF greater than 20%, using PANTHER Gene List 279 Analysis 36 . We observed a pattern for all three samples where most of the genes were categorized in two 280 major biological processes, "Cellular Process" and "Metabolic Process". Specifically, genes within "Cellular 281
Process" were subcategorized in sub processes as cell communication, cell proliferation and cell cycle (Fig.  282   4D-F) . Genes as Cit, Cdk9 and Stag1 are related to the control of cell cycle by regulating cytokinesis, 283 transcription and cohesion of sister chromatids after DNA replication, respectively. Importantly, Smarcb1 284 encodes a core subunit protein of the ATP-dependent SWI/SNF chromatin remodeling complex, and was 285 previously identified as a tumor suppressor 37 . Nap1l4, encodes a member of the nucleosome assembly protein 286 and has a role as a histone chaperone. Genes involved in cell communication and adhesion, as Cntnap5b, 287
Fras1, Sdk1 and Magi, were also enriched in our pathway analysis. In summary, Jak3 and Ikzf3 mutations 288 were identified as potential drivers of leukemogenesis in Mb1-CreDPB mice, based on the observation that 289 these genes are mutated in two of three leukemias, have high VAF, and have high levels of expression. 290
291
Recurrent mutations in Janus Kinase 3 (Jak3) and Janus Kinase 1 (Jak1) in leukemias from Mb1-292
CreDPB mice 293
Analysis of the impact of variants on protein expression showed that SNVs in leukemias 853 and 857 294 resulted in coding changes in Jak3 (R653H, V670A, and/or T844M) while the SNV in Jak1 in sample 854 295 resulted in a V657F substitution (Fig. 5A, 5B) . These genes encode for Jak1 and Jak3 that are critically 296 required for signaling through cytokine receptors IL7R and CRLF2 38 . Comparison of Jak3 and Jak1 protein 297 sequences among six different vertebrates showed that amino acids that underwent substitution in 298 consequence of a SNV were highly conserved between these species (Fig. 5A, 5B) . Sanger sequencing of 299 samples 853, 854 and 857 confirmed the presence of SNVs identified by WES in the Jak3, Jak1 and Ikzf3 300 genes (Supplementary Fig. 3 ). To determine whether these variants represent recurrent leukemia driver 301 mutations, we performed Sanger sequencing on a total of 19 Mb1-CreDPB leukemias using primers flanking 302 the regions containing the SNVs identified by WES. Interestingly, this examination revealed that Jak3 R653H 303 mutation was detectable in 5/19 leukemias analyzed. Jak1 mutations V657F or V655L showed even higher 304 recurrence than Jak3 mutation, being detectable in 10/19 leukemias (Fig. 5D) . Ikzf3 mutations were detected 305 only in samples 853 and 857, confirming the exome sequencing (Fig. 5C, 5D) . In summary, these data show 306 that leukemia in Mb1-CreDPB mice is accompanied by recurrent secondary driver mutations in Jak1 and 307
Jak3
. 308 309 R653H, V670A, and T844M amino acid substitutions in Jak3 confers survival and proliferation 310 advantages 311
We next tested whether R653H, V670A, and T844M amino acid substitutions in Jak3 were able to 312 confer growth advantage to normal cells. Site-directed mutagenesis was used to introduce these mutations to 313 the wild-type mouse Jak3 coding region in an MSCV-IRES-GFP vector (a kind gift from Dr. Kevin D. 314 Bunting). Pseudovirus was generated to spin-infect wild-type pro-B cells that grow in cultures containing 315 IL-7 and ST2 stromal cells. Pro-B cells were also infected with MSCV-Jak3 and a MSCV-empty vectors as 316 controls. Following infection, the cell lines were cultured at high (5% conditioned medium) and low IL-7 317 (0.5%). Flow cytometry was performed every two days for 14 days to determine the frequency of GFP + cells. 318
Pro-B cells infected with Jak3 mutations R653H, V670A, or T844M outgrew uninfected or control infected 319 pro-B cells at low and high IL-7 concentration (Fig. 6A, 6B) . Next, in order to verify whether Jak3 mutations 320 resulted in greater proliferation, cells infected with mutant Jak3 were plated at the initial concentration of 321 1x10 5 cells/ml in conditions of low and high IL-7. Cell numbers and the percentage of viable GFP + cells were 322 determined after cells were kept in culture for the period of four days. At low IL-7 concentration, pro-B cells 323 infected with Jak3 R653H, V670A, and T844M mutations showed a significant increase in the number of 324 GFP + cells after four days in culture (Fig. 6C, 6D) . Therefore, we conclude that T844M, R653H and V670A 325 amino acids substitutions were able to increase the proliferation of pro-B cells in conditions of low IL-7. 326
Taken together, these data indicate that Jak3 mutations identified in this analysis confer survival and growth 327 advantages to pro-B cells, consistent with a role as driver mutations. 328
Discussion 329
In this study, we showed that Mb1-CreDPB mice develop precursor B-ALL that is detectable in 330 mice by 11 weeks of age and results in a requirement for euthanasia in 100% of mice by median 18 weeks. 331
The latency of 11-18 weeks, and the variable frequency of leukemias expressing Ig, show that there is 332 clonal variability, suggesting that secondary driver mutations are required for disease progression. By 333 characterizing the mutation landscape of Mb1-CreDPB leukemias using whole exome sequencing coupled 334
with RNA-sequencing, we discovered that mutations in Jak1 and Jak3 represent recurrent secondary 335 driver mutations. Introduction of mutant Jak3 into wild type cells was sufficient to promote growth in 336 response to low IL-7 concentrations. Taken together, these results show that deletion of genes encoding 337
PU.1 and Spi-B result in leukemia by predisposition to additional de novo driver mutations in genes 338
encoding Janus kinases. We identified a number of single nucleotide variants (SNVs) in our analysis, which suggest that 355 several rounds of mutational events contributed to leukemogenesis. To select the potential leukemia 356 initiator lesions, we focused our attention in genes that were highly expressed and had high variant allelic 357 frequencies (VAF), reasoning that genes within this category are likely to have originated earlier in 358 leukemia progression. This analysis identified Aiolos (Ikzf3), Jak1 (Jak1) and Jak3 (Jak3) as potential 359 secondary driver mutations. These genes are involved in signaling downstream of cytokine receptors 360 during B cell development. Cytokine receptor genes are commonly mutated in human B-cell acute 361 lymphoblastic leukemias 47 , and mutations in Jak3 and Ikzf3 have recently emerged as novel mutated genes 362 in high-risk B-ALL 48 . In particular, our analysis focused on R653H, V670A, and T844M mutations in 363 Jak3. Jak3 R653H and V670A mutations were recently observed in B-ALL generated in activation-364 induced cytidine deaminase (AID) deficient mice 49 . Human equivalents of Jak3 R653H and V670A have 365 been described in human ALL (R657Q, V674F), and furthermore have been shown to function by 366 activation of proliferation in response to interleukin-7 50 . Importantly, human JAK3 V674F is sufficient to 367 induce T-cell acute lymphoblastic leukemia when retrovirally delivered to hematopoietic precursors 50 . 368 Jak1 missense mutations V655L or V657F were detectable in 10 of 19 leukemias in our analysis. Jak1 369 V657F also corresponds to a human JAK1 mutation that is a frequent driver in human B-ALL (V658F) 51 .
370
Interestingly JAK1 V658F mutation has been previously observed in T-cell acute lymphoblastic and acute 371 myeloid leukemias 52 . V658F is also thought to be paralogous to the JAK2 V617F mutation that functions 372 as a driver in more than 95% of cases of polycythemia vera 53 . In summary, the mutations identified in this 373 study in Jak1 and Jak3 are relevant to human leukemia. 374
Taken together, this study confirms that leukemia in Mb1-CreDPB mice is accompanied by de 375 novo recurrent secondary driver mutations in the Janus Kinase signaling pathway. Mutations in the JAK 376 signaling pathway are recurrent in human leukemia including the recently discovered Ph-like 377 classification that represents a high priority for discovering new therapies 9, 10 . In order to study the genetic 378 clonal evolution that underlies diseases such as Ph-like leukemia, there is still a need for mouse models. 379
In order to advance understanding, mouse models should have the following characteristics: 1) They 380 should develop leukemias with high penetrance and reproducibility, 2) they should replicate the genetic 381 and molecular heterogeneity of tumors and involve de novo mutations 3) they should occur in immune 382 competent mice, and 4) they should mimic that clinical behaviour of human disease 54, 55 . The Mb1-CreDPB 383 mouse model develops B-ALL with 100% penetrance by 18 weeks of age that is driven by heterogeneous 384 de novo driver mutations. This mouse model may be useful to determine the effects of molecular targeted 385 therapies on intratumoral heterogeneity and clonal evolution in B-ALL. 
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